ArticlePediatric nephrology (Berlin, Germany)2006
The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients.
Article in Pediatric nephrology (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01767350 (Study Aimed at Determining the Relation Between the Administered Dose and Exposure to Immunosuppressive Medication in Children After Solid Organ Transplantation), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study Aimed at Determining the Relation Between the Administered Dose and Exposure to Immunosuppressive Medication in Children After Solid Organ Transplantation
Who cites it
18 citing papers in PubMed.
- Early Acute Kidney Injury in Allogeneic Hematopoietic Cell Transplantation: Incidence, Severity, and Associated Factors in a 634-Recipient Cohort.European journal of haematology · 2026Observational
- An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.International journal of molecular sciences · 2021Article
- The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients.Pediatric nephrology (Berlin, Germany) · 2019Article
- Clinical aspects of tacrolimus use in paediatric renal transplant recipients.Pediatric nephrology (Berlin, Germany) · 2019Review
- Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.British journal of clinical pharmacology · 2017Article
- The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.Clinical pharmacokinetics · 2016Article
- Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Article
- Therapeutic drug monitoring in pediatric renal transplantation.Pediatric nephrology (Berlin, Germany) · 2015Review
- Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.British journal of clinical pharmacology · 2014Article
- A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.The AAPS journal · 2013Article
- Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.European journal of clinical pharmacology · 2013Article
- The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.European journal of clinical pharmacology · 2011Article
- Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients.Pharmaceutics · 2010Review
- Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.Pediatric nephrology (Berlin, Germany) · 2010Article
- Review
- Calcineurin inhibitors in pediatric renal transplant recipients.Paediatric drugs · 2007Review
- Renal transplantation in high-risk patients.Drugs · 2007Review
- Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.Clinical transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of our trial were to study the pharmacokinetics of tacrolimus in paediatric kidney transplant recipients. The study comprised 25 patients (median age 13 years, range 2-20 years) followed for 12 months; five pharmacokinetics profiles (within the first and second week and after 1 month, 6 months and 12 months) were obtained. Patients were divided into two groups: six children<6 years old and 19 older children. Tacrolimus was given at an initial dose of 0.15 mg/kg twice a day. Blood samples were drawn before and 1 h, 2 h, 3 h, 4 h, 6 h, 9 h and 12 h after drug administration. Patient and kidney survival rates were 100% at 1 year. At 6 months and 12 months creatinine clearance was 68.5+/-16.3 ml/min per 1.73 m2 and 64.0+/-15.2 ml/min per 1.73 m2 body surface area, respectively. Tacrolimus trough levels were 7.8+/-1.9 ng/ml and 7.3+/-2.5 ng/ml. The area under the concentration-time curve for 0 h to 12 h (AUC0-12) normalised to a dose of 0.15 mg/kg, increased with time from the kidney transplantation and stabilised after the 6th month post-transplantation. During the first month after transplantation the normalised tacrolimus concentration-time profiles were significantly greater in the older children (P<0.05); the actual doses were significantly greater in the younger children (P<0.05). In conclusion, initial doses of 0.15 mg/kg twice a day orally are safe and guarantee a satisfactory degree of immunosuppression, with our therapeutic regimen. Children<6 years old need to start with a 50% higher tacrolimus dose to achieve the same pharmacokinetic and immunosuppressive results.
Indexed as
Identifiers
16550361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.